Chimerix
- Country
- đşđ¸United States
- Ownership
- -
- Employees
- 72
- Market Cap
- $88M
- Introduction
Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded in April 2000 and is headquartered in Durham, NC.
A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease
- Conditions
- Interventions
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2021-07-16
- Lead Sponsor
- Chimerix
- Target Recruit Count
- 5
- Registration Number
- NCT02439970
- Locations
- đşđ¸
St. Vincent Medical Center, Los Angeles, California, United States
đşđ¸University of Colorado Hospital/Health Science Center, Aurora, Colorado, United States
đşđ¸Yale New Haven Hospital, New Haven, Connecticut, United States
A Multicenter Study to Obtain Retrospective Data for Subjects Previously Diagnosed With Adenovirus Infection to Serve as Matched Historical Controls for Study CMX001-304
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- Chimerix
- Target Recruit Count
- 100
- Registration Number
- NCT02420080
- Locations
- đşđ¸
University of Chicago, Chicago, Illinois, United States
đşđ¸Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
đşđ¸Emory University, Atlanta, Georgia, United States
An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease
- First Posted Date
- 2014-10-22
- Last Posted Date
- 2015-02-02
- Lead Sponsor
- Chimerix
- Registration Number
- NCT02271347
The Chimerix CMX001 Registry
- First Posted Date
- 2014-06-19
- Last Posted Date
- 2019-05-17
- Lead Sponsor
- Chimerix
- Target Recruit Count
- 550
- Registration Number
- NCT02167685
- Locations
- đşđ¸
Children's Hospital of LA, Los Angeles, California, United States
đşđ¸Emory University, Atlanta, Georgia, United States
đşđ¸Winship Cancer Institute Emory University, Atlanta, Georgia, United States
Study to Assess the Safety and Efficacy of Brincidofovir in Treatment of Early Versus Late Adenovirus Infection
- First Posted Date
- 2014-03-14
- Last Posted Date
- 2021-08-13
- Lead Sponsor
- Chimerix
- Target Recruit Count
- 201
- Registration Number
- NCT02087306
- Locations
- đşđ¸
Children's Hospital, New Orleans, Louisiana, United States
đşđ¸Children's National Health System, Washington, District of Columbia, United States
đşđ¸Montifore Medical Center, Bronx, New York, United States
A Pilot Study of Dociparstat Sodium (ODSH) in Acute Myeloid Leukemia
- First Posted Date
- 2014-02-06
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Chimerix
- Target Recruit Count
- 12
- Registration Number
- NCT02056782
A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-01-16
- Last Posted Date
- 2021-04-30
- Lead Sponsor
- Chimerix
- Registration Number
- NCT02038699
- Locations
- đşđ¸
Massachusetts General Hospital, Boston, Massachusetts, United States
Ph I Safety and Efficacy of ODSH in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia
- First Posted Date
- 2013-04-30
- Last Posted Date
- 2021-11-10
- Lead Sponsor
- Chimerix
- Target Recruit Count
- 10
- Registration Number
- NCT01843634
- Locations
- đşđ¸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients
- First Posted Date
- 2013-01-16
- Last Posted Date
- 2021-07-21
- Lead Sponsor
- Chimerix
- Target Recruit Count
- 452
- Registration Number
- NCT01769170
- Locations
- đşđ¸
Johns Hopkins University, Baltimore, Maryland, United States
đşđ¸The Universit of Iowa, Iowa City, Iowa, United States
đşđ¸University of California, San Diego-Moores Cancer Center, La Jolla, California, United States
Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2011-10-28
- Last Posted Date
- 2022-06-06
- Lead Sponsor
- Chimerix
- Target Recruit Count
- 60
- Registration Number
- NCT01461915
- Locations
- đşđ¸
Cleveland Clinic Florida, Weston, Florida, United States
đşđ¸Scripps Clinic Torrey Pines ( Green Hospital), La Jolla, California, United States
đşđ¸Marin Cancer Care, Greenbrae, California, United States